Kent Imaging said today it inked a strategic partnership with SerenaGroup aiming to improve wound tissue assessments.
Through the deal, wound healing research firm SerenaGroup will adopt use of Kent’s KD203 near infrared imaging technology designed for measuring oxygenation, which Calgary, U.K.-based Kent Imaging touted as the “best biomarker” of tissue healing.
“We are pleased to introduce Kent’s imaging system into the wound care protocol at our clinics. One of the most troublesome and elusive criteria in treating wounds is the timely and accurate assessment of viable tissue. Kent’s device will propel us a long way down the healing path with a technology that has been lacking across the board in the Wound Care space,” SerenaGroup founder & medical director Dr. Serena said in a prepared statement.
The KD203 device reports oxygen saturation, relative oxyhemoglobin levels and relative deoxyhemoglobin levels in superficial tissue. The system displays a 2D color-coded image to aid clinicians in determining at risk tissue and improve treatment decisions, Kent said.
“Our joint belief is that we can improve patient care and outcomes by significantly improving clinically relevant data that is required to assess and manage wounds. We are excited to be partnering with SerenaGroup and with Dr. Serena who has dedicated his career to improving patient outcomes in wound care,” Kent Imaging CEO Pierre Lemire said in a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.